$20.16+1.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $19.2M | $348K | +5,406.90% |
| Profit | -$17.4M | -$72M | +75.85% |
| Profit per share | -$0.14 | -$0.61 | +77.05% |
| Free Cash Flow | -$40M | -$32.8M | -21.76% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
NewAmsterdam Pharma Company N.V. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“During the second quarter, we continued to build momentum across our regulatory, clinical, and scientific priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from NewAmsterdam Pharma Company N.V.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.